

# BOSTON SCIENTIFIC CORP

ISIN: US1011371077 WKN: 101137107 Asset Class: **Stock**

## Company

2024/04/26 22:00:02

**Boston  
Scientific**

Price  
**73.17**  
USD

Difference  **-0.12% (-0.09)**



## Contact Details

BOSTON SCIENTIFIC  
CORP.

Tel: +1-508-683-4000

--

Fax: +

300 Boston Scientific Way

Web:

<http://www.bostonscientific.com>

01752-1234 Marlborough

E-mail: -

## Company Profile

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023           |                        | 2022           |                        | 2021           |                        |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                       | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| <b>Current assets</b>                 | 6,514,000,000  |                        | 5,760,000,000  |                        | 6,317,000,000  |                        |
| <b>Common stock capital</b>           |                | 17,000,000             |                | 17,000,000             |                | 17,000,000             |
| <b>Fixed assets</b>                   | 28,622,000,000 |                        | 26,709,000,000 |                        | 25,912,000,000 |                        |
| <b>Equity capital of a company</b>    |                | 19,530,000,000         |                | 17,573,000,000         |                | 16,622,000,000         |
| <b>Cash and cash equivalents</b>      | 995,000,000    |                        | 1,077,000,000  |                        | 2,113,000,000  |                        |
| <b>Accrued liabilities</b>            |                | 172,000,000            |                | 212,000,000            |                | 284,000,000            |
| <b>Other assets</b>                   | -              |                        | -              |                        | -              |                        |
| <b>Current liabilities</b>            |                | 4,933,000,000          |                | 3,803,000,000          |                | 4,274,000,000          |
| <b>Prepayments and accrued income</b> | -              |                        | -              |                        | -              |                        |
| <b>Non-current liabilities</b>        |                | 10,673,000,000         |                | 11,093,000,000         |                | 11,333,000,000         |
| <b>Different income</b>               |                | -                      |                | -                      |                | -                      |
| <b>Other liabilities</b>              |                | 1,406,000,000          |                | 1,475,000,000          |                | 1,546,000,000          |
| <b>Total assets</b>                   | 35,136,000,000 | 35,136,000,000         | 32,469,000,000 | 32,469,000,000         | 32,229,000,000 | 32,229,000,000         |

## Balance notes

|                            | 2023    | 2022    | 2021    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | US-GAAP | US-GAAP | US-GAAP |
| <b>Employees</b>           | 48,000  | 45,000  | 41,000  |
| <b>Equity ratio</b>        | 56.29%  | 54.12%  | 51.57%  |
| <b>Debt-equity ratio</b>   | 77.65%  | 84.77%  | 93.89%  |

## Others

|                         | 2023   | 2022   | 2021  |
|-------------------------|--------|--------|-------|
| <b>Tax Expense Rate</b> | 19.80% | 38.83% | 3.35% |

# BOSTON SCIENTIFIC CORP

ISIN: US1011371077 WKN: 101137107 Asset Class: Stock

## Income statement

|   | 2023           | 2022           | 2021           |
|---|----------------|----------------|----------------|
| Turnover  | 14,240,000,000 | 12,682,000,000 | 11,888,000,000 |
| Net income  | 1,593,000,000  | 698,000,000    | 1,040,000,000  |
| EBIT  | 2,088,831,000  | 1,490,687,000  | 1,328,066,600  |
| Operating income before taxes                                 | 1,985,000,000  | 1,141,000,000  | 1,076,000,000  |
| Cash Flow   | 2,503,000,000  | 1,526,000,000  | 1,871,000,000  |
| Net interest income   | -250,000,000   | -454,000,000   | -345,000,000   |
| Research and development expenses                             | 1,414,000,000  | 1,323,000,000  | 1,204,000,000  |
| Income taxes  | 393,000,000    | 443,000,000    | 36,000,000     |
| Result from investments in subsidiaries, associates and other | -              | -              | -              |
| Revenues per employee   | 277,265        | 263,391        | 270,988        |

## Board of Directors

## Members of Management Board

|                      |                               |
|----------------------|-------------------------------|
| Ellen Zane           | Member of Board of Directors  |
| Jessica Mega         | Member of Board of Directors  |
| Charles Dockendorff  | Member of Board of Directors  |
| Dave Roux            | Member of Board of Directors  |
| David Wichmann       | Member of Board of Directors  |
| Edward Ludwig        | Member of Board of Directors  |
| John Sununu          | Member of Board of Directors  |
| Nelda Connors        | Member of Board of Directors  |
| Susan Morano         | Member of Board of Directors  |
| Yoshiaki Fujimori    | Member of Board of Directors  |
| Michael F. Mahoney   | Chairman of Managing Board    |
| Arthur Butcher       | Member of Executive Committee |
| Daniel J. Brennan    | Member of Executive Committee |
| Eric Thépaut         | Member of Executive Committee |
| Jeff Mirviss         | Member of Executive Committee |
| Jodi Eddy            | Member of Executive Committee |
| Joseph M. Fitzgerald | Member of Executive Committee |
| Kenneth Stein        | Member of Executive Committee |
| Mary Beth Moynihan   | Member of Executive Committee |